RxDoctor Payments Data

Sucharit Joshi, MD

Nephrology · Portsmouth, NHNPI 1114045184

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $4,885 of the $5,833 with a category attached, or 83.7%. 6 manufacturers reported payments, led by CSL Behring at 38.6% of the total. 2024 is the largest year on record at $4,375, 3.1 times the $1,410 reported in 2019. Among nephrology clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,833in general payments, 2019–2025

Across 34 payments — averaging $171.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$2K
  • Alnylam Pharmaceuticals Inc.$2K
  • Boehringer Ingelheim International GmbH$1K
  • Amgen$20
  • Calliditas Therapeutics US Inc.$16
  • Vifor Pharma, Inc.$12
$2,179,531in research payments, 2019–2025

Across 543 payments — averaging $4013.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim International GmbH$641K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$515K
  • CSL Behring$349K
  • GSK$314K
  • Akebia Therapeutics Inc$286K
  • Alnylam Pharmaceuticals Inc.$58K
  • plus $16K from 3 others

What the payments were for

  • Travel & lodging$4,88584%
  • Food & beverage$91616%
  • Education$321%

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,833 in reported general payments places this provider in the 90th percentile of 33 nephrology providers in New Hampshire.

See all nephrology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$176,729
Medicare patients
521
Services billed
1,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuryxiaFerric Citrate39$71,005
VelphoroSucroferric Oxyhydroxide15$49,731
LokelmaSodium Zirconium Cyclosilicate19$22,386
FarxigaDapagliflozin Propanediol16$20,734
JardianceEmpagliflozin12$20,584
Sevelamer Carbonate48$6,824
Eplerenone13$2,329
Losartan Potassium169$2,019
Amlodipine Besylate136$949
Carvedilol58$727
Valsartan12$703
Potassium Chloride29$668
Spironolactone41$610
Doxazosin Mesylate24$463
Metolazone11$391

Paid to pharmacies, not to this prescriber.

Other nephrology in Portsmouth

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →